N‐desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The development of anticonvulsant tolerance during 10 days treatment with either clobazam or its principal metabolite, N‐desmethylclobazam (NDMC), was compared in mice using an i.v. infusion of pentylenetetrazole as the convulsive stimulus. Subsequently the anticonvulsant activity of NDMC was assessed in patients with refractory epilepsy. In mice, a highly significant tolerance (P less than 0.001) developed to clobazam (10 mg kg‐1 twice daily). During the same period, there was no significant change (P greater than 0.05) in the protection afforded by NDMC (40 or 80 mg kg‐1 twice daily) although some reduction in anticonvulsant activity was apparent. NDMC (30 mg once daily) was given to nine patients with frequent complex partial and/or grand mal seizures who had become tolerant to the anticonvulsant effect of clobazam. Seven of the patients had been free from benzodiazepine therapy for at least 2 weeks, while the other two patients were switched directly from clobazam. Eight of the nine patients showed a favourable response to NDMC. In the seven who had been given a holiday from clobazam the response to NDMC was similar to the initial response to clobazam and was achieved at plasma NDMC concentrations in the same range as those seen during clobazam administration (1000‐3000 ng ml‐1). It is concluded that NDMC is active as an anticonvulsant in man and there is evidence from the animal studies to suggest that it may be preferable to clobazam.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of tolerance to the anticonvulsant effect of diazepam in dogs
Frey, H.-H., Philippin, H.-P., & Scheuler, W. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90365-0 · Cited by 80
Differences between the tolerance characteristics of two anticonvulsant benzodiazepines
Gent, J. P., Feely, M. P., & Haigh, J. R. M. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90520-x · Cited by 66
Self-citationClobazam: pharmacological and therapeutic profile
Hanks, G. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb04685.x · Cited by 32
Cited by
Dichter, M. A., & Brodie, M. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606133342407 · Cited by 340
A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam
Kosaki, K., Tamura, K., Sato, R., Samejima, H., Tanigawara, Y., & Takahashi, T. (2004) · Brain and Development · doi:10.1016/j.braindev.2004.02.010 · Cited by 80
Lack of anticonvulsant tolerance with RU 32698 and Ro 17-1812
Feely, M., Boyland, P., Picardo, A., Cox, A., & Paul Gent, J. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90482-2 · Cited by 34
Self-citationGarratt, J. C., Paul Gent, J., Feely, M., & Haigh, J. R. M. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90351-2 · Cited by 34
Self-citationLong‐term benzodiazepine treatment: Is it ever justified?
Chen, Y., & Lader, M. (1990) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.470050403 · Cited by 9
Metadata
- Authors
- Haigh, Jr., Pullar, T., Gent, J., Dailley, C., & Feely, M.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1987-02
- Volume
- 23
- Issue
- 2
- Pages
- 213-218
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2086516145
- Cited by
- 47
- References
- 3
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: N‐desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy? https://app.cochat.ai/papers/10.1111/j.1365-2125.1987.tb03032.x
- The paper
- Haigh, Jr., Pullar, T., Gent, J., Dailley, C., & Feely, M. (1987). N‐desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy? British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.1987.tb03032.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.